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Mendelian randomization (MR) permits causal inference between exposures and a disease. It can be compared
with randomized controlled trials. Whereas in a randomized controlled trial the randomization occurs at entry into
the trial, in MR the randomization occurs during gamete formation and conception. Several factors, including time
since conception and sampling variation, are relevant to the interpretation of an MR test. Particularly important is
consideration of the ‘‘missingness’’ of genotypes that can be originated by chance, genotyping errors, or clinical
ascertainment. Testing for Hardy-Weinberg equilibrium (HWE) is a genetic approach that permits evaluation of
missingness. In this paper, the authors demonstrate evidence of nonconformity with HWE in real data. They also
perform simulations to characterize the sensitivity of HWE tests to missingness. Unresolved missingness could
lead to a false rejection of causality in an MR investigation of trait-disease association. These results indicate that
large-scale studies, very high quality genotyping data, and detailed knowledge of the life-course genetics of the
alleles/genotypes studied will largely mitigate this risk. The authors also present a Web program (http://www.
oege.org/software/hwe-mr-calc.shtml) for estimating possible missingness and an approach to evaluating missing-
ness under different genetic models.
epidemiologic methods; genetics; Hardy-Weinberg equilibrium; random allocation; research design
Abbreviations: APOE, apolipoprotein E; HWE, Hardy-Weinberg equilibrium; MR, Mendelian randomization; SNP, single nucleo-
tide polymorphism; WTCCC, Wellcome Trust Case Control Consortium.
Epidemiologic association studies are susceptible to un-
resolved confounding, reverse causation, and selection bias
(1). Mendelian randomization (MR) is an epidemiologic
method that, through the use of informative genotypes, per-
mits the testing of causal relations between exposures and
diseases. MR is based on the assumption that the association
between a disease and a genetic polymorphism of known
function (that mimics the biologic link between a proposed
exposure and disease) is not generally susceptible to reverse
causation or confounding (1). Thus, for example, if it is
known that there is an association between a plasma protein
and a disease, the direction of that association can be tested
if genotypes of the gene encoding the protein are associated
with the level of the protein. Because the quantity of the
protein cannot cause the genotype but the genotype can in-
ﬂuence the quantity of the protein, if the genotype is also
associated with the disease it may be inferred that the level
of the plasma protein is causally inﬂuencing the disease.
The MR approach is conceptually analogous to a random-
ized controlled trial (see Figure 1). Randomization in ran-
domized controlled trials is undertaken at entry into the trial,
and since many trials concern major diseases arising in later
life, many studies are of older persons. The same applies to
many cohort studies upon which MR will be based. Ran-
domization in MR (random assignment to genotype) occurs
during gamete formation and conception (1). This means
that the principle of MR has the potential to strengthen in-
ference from an observational study (such as a cohort study)
toward the inferential robustness of a randomized controlled
trial. In randomized controlled trials, one analyzes the data
on the basis of ‘‘intention to treat’’ in most cases—this en-
sures that all possible differences between drug and placebo
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tomatchthis,thereisaneedtoanalyzethedataon‘‘intention
to MR.’’ It follows that the randomly breeding population
asawholesuitsanMRtest.However,whenarandomsample
is taken from a population, especially at a time point likely
to be far from the original fertilization (i.e., randomization)
events,the nature of the sample needs tobe carefully consid-
ered with respect to ‘‘intention to MR.’’
A particular genetic feature of randomly breeding popu-
lations is that of Hardy-Weinberg equilibrium (HWE) (2, 3).
Since alleles of diploid loci are randomly reassorted at each
new conception, it follows that for allele frequencies p and q
(where p þ q ¼ 1) for biallelic loci, the frequencies of ge-
notypes are expressed by the expansion (p þ q)
2.
In genetics, the test of whether the proportions of geno-
types observed in a population sample are consistent with
the prediction (p
2,2 pq, and q
2) offers a fundamental test of
biologic ascertainment for the genotypes. A sample from
a homogeneous randomly mating population should only
deviate from perfect HWE by small chance amounts,
conforming to parametric sampling statistics. Large, statis-
tically signiﬁcant deviations are often caused by quality
issues with laboratory typing data. However, given high-
quality genotyping data, the HWE feature offers the
opportunity to look for possible biologic ascertainment
biases for the population sample relative to the genotype
of interest.
In this paper, we consider the relations between sample
HWE testing, genotyping error, chance deviations from ex-
act HWE in the sample, and the use of genotype as an in-
strumental variable for MR analyses. We also present a Web
tool for estimating possible missingness and a scheme for
examining missingness under different genetic models
(additive, threshold, heterosis). This approach more se-
curely equates the principle of ‘‘intention to MR’’ with
the ‘‘intention to treat’’ analysis principle of randomized
controlled trials.
MATERIALS AND METHODS
We consider studies in which either there is an additive
effect per allele in subjects or 1 homozygous group would
be considered the phenotypically different group for trait
and disease. For a locus with 2 alleles P and Q and overall
population frequencies p and q, and taking a sample of size
N, the genotypes in the possible resultant sample can be
parameterized. When considering the sampling of P homo-
zygotes, in a sample of N subjects, the variance of the ob-
served number l relative to the expected number Np
2 will be
that of a binomial distribution—that is, Np
2(1   p
2). These
values were used to determine the standard deviation r of
the observed number in the sample relative to that expected
from the population if chance variation did not occur. In
turn, this permitted modeling for chosen 0 < p < 1 and
a chosen boundary unlikelihood of sample characteristics
(e.g., the 95% conﬁdence interval (computed as l 6
1.96r) for samples that would usually be observed), to ex-
amine missingness which could be due to chance but could
also be due to biologic ascertainment bias. Additionally, the
‘‘selective’’ effects of genotyping problems (e.g., failure to
genotype heterozygotes because their 2 allelic signals may
be weaker than the double-strength signal in homozygotes)
were modeledbychanging1genotypegroupbyaproportion
multiplier k, arbitrarilyvaried from a 20% loss to a 20% gain
(from 30.8 to 31.2).
We started the simulations with allelic frequencies ptrue
and qtrue and computed the expected true values for the 2
homozygote groups and for the heterozygotes assuming
HWE. We then computed the number of persons in the
no-call group who were lost/gained. These numbers were
Figure 1. Mendelian randomization and randomized controlled trials. Adapted from the paper by Hingorani and Humphries (12). HWE, Hardy-
Weinberg equilibrium.
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true for
homozygotes. For the computation of heterozygote losses/
gains, we computed pfalse and qfalse—that is, the erroneous
values of p and q that are obtained according to the loss
or gain (chance or genotype assay-related or genotype-
dependent ascertainment-related) of a genotype group de-
pendent on k. Calculations were performed using programs
written in Python (http://www.python.org).
pfalse ¼
pallelesactuallyobserved
totalallelesactuallyobserved
;
p false ¼
2Np2
true þ 2kNptrueqtrue
2½N   2ð1   kÞNptrueqtrue 
;
p false ¼
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1   k

p2
true þ kptrue
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1   k

p2
true   2

1   k

ptrue
;
and qfalse ¼ 1   pfalse.
Using both values, we computed the expected numbers of
bothhomozygotegroupsandtheheterozygotes.Theobserved
number of heterozygotes was computed by subtracting/
adding the number of the no-call group to the expected true
values for the heterozygotes. We then computed the HWE
Pearson v
2 value for expected genotype counts versus ob-
served genotype counts.
For the computation of homozygote losses or gains, we
followed an analogous procedure, but with
p false ¼
2kNp2
true þ 2Nptrueqtrue
2

N  

1   k

Np2
true

and
pfalse ¼
ptrue  

1   k

p2
true
1  

1   k

p2
true
:
To approach the typical study size generally anticipated for
MR, we considered a range of N’s from 1,000 (expected to
be sufﬁcient for major genotype effects) to 100,000 (be-
lieved to be reasonably powered for modest complex trait
effects (4)).
We consideredarangeof caseswithperfect HWE, forgiven
combinations of allele frequencies (1 > p > 0) and sample
sizes (100,000 > N > 5,000). We computed the 95% conﬁ-
dence limits of allele frequency from the formula (5)
Var

ˆ p

¼
ˆ pð1   ˆ pÞ
2N
:
We estimated expected genotypic counts from these
estimates and computedthe HWE v
2 value. Analogous anal-
yses were carried out for gain/loss of homozygotes and
heterozygotes.
We evaluated the HWE v
2 distributions for the single nu-
cleotide polymorphisms (SNPs) analyzed in 2 genome-wide
association studies, the study by the Wellcome Trust Case
Control Consortium (WTCCC) (6) and the Framingham
Study (7). For the WTCCC study, we computed the
HWE v
2 values for more than 400,000 SNPs from the
observed genotype counts for each SNP in more than
2,000 controls. For the Framingham Study, we computed
the HWE v
2 values from the P values available for nearly
100,000 SNPs analyzed for association with prostate can-
cer in more than 600 unselected men. We also analyzed
the HWE v
2 value from publications in the literature that
reported the HWE v
2, the P value for the HWE v
2 test, or
the genotypic counts for the apolipoprotein E (APOE) poly-
morphism. We considered the ﬁrst 30 studies (see Web
Table 1, which is posted on the Journal’s Web site (http://aje.
oxfordjournals.org/))observedwiththescientiﬁcresearchtool
‘‘scirus’’ (http://www.scirus.com/) using the search terms
‘‘APOE’’ and ‘‘Hardy-Weinberg’’ on April 11, 2008.
We created Q-Q plots in SPSS, version 15.0 (SPSS, Inc.,
Chicago, Illinois), in order to compare the observed and
expected v
2 values (with 1 df) for WTCCC controls and
for cases with the 7 diseases analyzed in the WTCCC study.
We alsoanalyzed the Q-Q plots forthe Framingham prostate
cancer cases and for the 30 studies of APOE.
Since
ð2NpqÞ
2
4Np2Nq2 ¼ 1
and 2Npq, Np
2, and Nq
2 represent the 3 genotype counts in
a sample in perfect HWE (v
2 ¼ 0), it is possible to use 2
groups’ observed values to estimate the expected value for
the third group, and hence for each group to assess possible
missingness (or excess). We developed a Web program
(http://www.oege.org/software/hwe-mr-calc.shtml) both to
conduct a standard HWE test (Pearson v
2) based on the 3
groups and to calculate counts (changing any 1 group) to
create perfect HWE.
We applied the effect of missingness and deviations from
HWE to an MR example consisting of a sample of 10,000
persons with genotypic, intermediate trait, and outcome in-
formation. We added persons who were missing based on
HWE and computed the signiﬁcance of the new MR studies.
MR analyses were carried out in Stata/IC 10.0 for Windows
(Stata Corporation, College Station, Texas) using the com-
mand ‘‘ivregress.’’
RESULTS
In Web Table 2 (http://aje.oxfordjournals.org/), for
representative values of p (0 < p < 1) and N (1,000  
N   100,000), we present r/l and 95% conﬁdence intervals
for expected numbers of p homozygotes. Estimated r/l
ranged from 0.10% to 3.16% and was inversely related to
both p and N. Table 1 shows a subset of these results.
Table 2 gives values of N and p with 1 homozygote group
adjusted to the lower 95% conﬁdence limit. Table 3 applies
thesameapproachtoheterozygotes.Resultsforalargerrange
of conditions can be seen in Web Tables 3 and 4 (http://aje.
oxfordjournals.org/). In each instance, these demon-
strate a loss of persons in 1 genotype group, which could
frequently occur by chance, through genotyping failure, or
Hardy-Weinberg Equilibrium and Mendelian Randomization 507
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that in most instances, the v
2 values would generate a ﬁrm
conclusion: ‘‘no signiﬁcantdeviationfromHWE.’’ TheHWE
test is insensitive to heterozygote loss (for detection of the
Table 2. Deviation From Hardy-Weinberg Equilibrium for Sample Sizes of 5,000, 20,000, and 50,000 and for Allele Frequencies Ranging From
0.05 to 0.95, After Subtracting From the Homozygote 1 Group a Number Equivalent to 1.96 Standard Deviations
Sample Size ptrue
a Hz1 True
a Het True
a Hz2 True
a pfalse
b Hz1 Exp
c Het Exp
c Hz2 Exp
c Hz1 Obs
d No Call
d x
2e
5,000 0.05 13 475 4,513 0.0487 12 462 4,519 6 7 3.65
5,000 0.20 200 1,600 3,200 0.1956 190 1,565 3,217 173 27 2.48
5,000 0.50 1,250 2,500 1,250 0.4939 1,205 2,470 1,265 1,190 60 0.75
5,000 0.80 3,200 1,600 200 0.7973 3,136 1,595 203 3,133 67 0.06
5,000 0.95 4,513 475 13 0.9496 4,471 475 13 4,471 41 0.00
20,000 0.05 50 1,900 18,050 0.0493 49 1,875 18,063 36 14 3.55
20,000 0.20 800 6,400 12,800 0.1978 781 6,330 12,835 746 54 2.42
20,000 0.50 5,000 10,000 5,000 0.4970 4,910 9,940 5,030 4,880 120 0.73
20,000 0.80 12,800 6,400 800 0.7987 12,672 6,389 805 12,667 133 0.06
20,000 0.95 18,050 1,900 50 0.9498 17,968 1,900 50 17,968 82 0.00
50,000 0.05 125 4,750 45,125 0.0496 123 4,710 45,145 103 22 3.52
50,000 0.20 2,000 16,000 32,000 0.1986 1,969 15,890 32,055 1,914 86 2.40
50,000 0.50 12,500 25,000 12,500 0.4981 12,358 24,905 12,548 12,310 190 0.73
50,000 0.80 32,000 16,000 2,000 0.7992 31,798 15,983 2,008 31,790 210 0.06
50,000 0.95 45,125 4,750 125 0.9499 44,995 4,749 125 44,995 130 0.00
Abbreviations: Exp, expected; Het, heterozygote; Hz, homozygote; Obs, observed.
a ptrue are the allele frequencies used to start the simulations. They were also used to estimate the true frequencies of homozygotes (Hz1 True
and Hz2 True) and heterozygotes (Het True) assuming Hardy-Weinberg equilibrium.
b pfalse are the allele frequencies observed after subtracting 1.96 standard deviations from the homozygote 1 group.
c Hz1 Exp, Het Exp, and Hz2 Exp are the expected values of the 3 genotype groups computed from pfalse and qfalse (1   pfalse).
d Hz1 Obs are the observed values for each genotype group after subtracting 1.96 standard deviations from the homozygote 1 group (which
equates to the number presented in the ‘‘No Call’’ column). The observed values of the other 2 genotype groups used to compute the deviations
from Hardy-Weinberg equilibrium (Het Obs and Hz2 Obs) are equal to Het True and Hz2 True, respectively.
e Hardy-Weinberg equilibrium v
2 value.
Table 1. Measures of Dispersion for Sample Sizes of 5,000, 20,000, and 50,000 and for Allele
Frequencies (p and q) Ranging From 0.05 to 0.95
Sample Size pq s
a 95% Conﬁdence Interval
ms /m
b
Lower Bound Upper Bound
5,000 0.05 0.95 3.53  6.92 6.92 250 0.0141
5,000 0.20 0.80 13.86  27.16 27.16 1,000 0.0139
5,000 0.50 0.50 30.62  60.01 60.01 2,500 0.0122
5,000 0.80 0.20 33.94  66.52 66.52 4,000 0.0085
5,000 0.95 0.05 20.98  41.11 41.11 4,750 0.0044
20,000 0.05 0.95 7.06  13.84 13.84 1,000 0.0071
20,000 0.20 0.80 27.71  54.32 54.32 4,000 0.0069
20,000 0.50 0.50 61.24  120.02 120.02 10,000 0.0061
20,000 0.80 0.20 67.88  133.05 133.05 16,000 0.0042
20,000 0.95 0.05 41.95  82.22 82.22 19,000 0.0022
50,000 0.05 0.95 11.17  21.89 21.89 2,500 0.0045
50,000 0.20 0.80 43.82  85.88 85.88 10,000 0.0044
50,000 0.50 0.50 96.82  189.78 189.78 25,000 0.0039
50,000 0.80 0.20 107.33  210.37 210.37 40,000 0.0027
50,000 0.95 0.05 66.33  130.01 130.01 47,500 0.0014
a Standard deviation of the observed number of subjects in the sample.
b Mean of the observed number of subjects in the sample.
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of p, and is only sensitive to homozygote loss where p has
a low value. As an example, for N ¼ 5,000 and p ¼ 0.2, 200
rare homozygotes would be expected, but within the 95%
conﬁdence interval, this value could range from 173 to 227.
In this example, the HWE test v
2 value was 2.48, well below
the 5% limit (v
2  3.84) typically used for samples in which
all 3 genotype groups would be free to vary by chance. There
is, nonetheless, deviation from perfect HWE (v
2 ¼ 0) and
(assuming perfect genotyping) uncertainty as to whether this
is due to chance or clinical ascertainment bias.
Tables 4 and 5 present combinations of allele frequency p,
sample size N, and proportional multiplier k (0.8   k   1.2),
modifying the observed number of 1 genotype group such
that HWE testing would suggest no signiﬁcant deviation
from HWE. Although a signiﬁcant deviation from HWE is
more likely with largevalues of N and k (Web Tables 5 and 6
(http://aje.oxfordjournals.org/)), there is a wide range of ob-
served population samples in which potential ascertainment
bias would not be recognized under a usual statistical test.
These (for HWE v
2 < 3.84) are shown in Web Figure 1
(http://aje.oxfordjournals.org/) as 3-dimensional plots with
axes for N, p, and j1   kj. Web Figure 1 shows that a greater
variation of the parameter j1   kj in homozygotes results in
more nonsigniﬁcant deviations from HWE for homozygotes
than for heterozygotes.
Web Table 7 (http://aje.oxfordjournals.org/) shows the
boundaries of allele frequencies and the associated v
2 values
observed for a combination of allele frequencies and sample
sizes in situations of perfect HWE from observed allele
frequencies. The maximum values of HWE v
2 computed
from the 95% conﬁdence interval allele frequencies range
from 3.56 to 4.18.
For gain/loss of heterozygotes (Web Table 8 (http://
aje.oxfordjournals.org/)), the maximum difference between
v
2 computed from the 95% conﬁdence interval of allele
frequencies and v
2 computed from the observed allele
frequencies is 1,132 (corresponding to j1   kj¼0.20,
Table 3. Deviation From Hardy-Weinberg Equilibrium for Sample Sizes of 5,000, 20,000, and 50,000 and for Allele Frequencies Ranging From
0.05 to 0.95, After Subtracting From the Heterozygote Group a Number Equivalent to 1.96 Standard Deviations
Sample Size ptrue
a Hz1 True
a Het True
a Hz2 True
a pfalse
b Hz1 Exp
c Het Exp
c Hz2 Exp
c Het Obs
d No Call
d x
2e
5,000 0.05 13 475 4,513 0.0463 11 438 4,511 434 41 0.36
5,000 0.20 200 1,600 3,200 0.1961 190 1,556 3,190 1,535 65 0.86
5,000 0.50 1,250 2,500 1,250 0.5000 1,233 2,465 1,233 2,431 69 0.97
5,000 0.80 3,200 1,600 200 0.8039 3,190 1,556 190 1,535 65 0.86
5,000 0.95 4,513 475 13 0.9537 4,511 438 11 434 41 0.36
20,000 0.05 50 1,900 18,050 0.0482 46 1,826 18,046 1,819 81 0.34
20,000 0.20 800 6,400 12,800 0.1980 779 6,312 12,779 6,271 129 0.85
20,000 0.50 5,000 10,000 5,000 0.5000 4,965 9,931 4,965 9,861 139 0.97
20,000 0.80 12,800 6,400 800 0.8020 12,779 6,312 779 6,271 129 0.85
20,000 0.95 18,050 1,900 50 0.9518 18,046 1,826 46 1,819 81 0.34
50,000 0.05 125 4,750 45,125 0.0488 119 4,634 45,119 4,621 129 0.34
50,000 0.20 2,000 16,000 32,000 0.1988 1,967 15,861 31,967 15,796 204 0.84
50,000 0.50 12,500 25,000 12,500 0.5000 12,445 24,890 12,445 24,781 219 0.96
50,000 0.80 32,000 16,000 2,000 0.8012 31,967 15,861 1,967 15,796 204 0.84
50,000 0.95 45,125 4,750 125 0.9512 45,119 4,634 119 4,621 129 0.34
Abbreviations: Exp, expected; Het, heterozygote; Hz, homozygote; Obs, observed.
a ptrue are the allele frequencies used to start the simulations. They were also used to estimate the true frequencies of homozygotes (Hz1 True
and Hz2 True) and heterozygotes (Het True) assuming Hardy-Weinberg equilibrium.
b pfalse are the allele frequencies observed after subtracting 1.96 standard deviations from the heterozygote group.
c Hz1 Exp, Het Exp, and Hz2 Exp are the expected values of the 3 genotype groups computed from pfalse and qfalse (1   pfalse).
d Het Obs are the observed values for each genotype group after subtracting 1.96 standard deviations from the heterozygote group (which
equates to the number presented in the ‘‘No Call’’ column). The observed values of the other 2 genotype groups used to compute the deviations
from Hardy-Weinberg equilibrium (Hz1 Obs and Hz2 Obs) are equal to Hz1 True and Hz2 True, respectively.
e Hardy-Weinberg equilibrium v
2 value.
Table 4. Hardy-Weinberg v
2 Values (in Parentheses) for Particular Combinations of Allele
Frequency, Gain/Loss of Homozygotes, and Sample Size
Allele Frequency Gain/Loss, % Sample Size
0.05 65 5,000 (0.03), 100,000 (0.57)
0.05 (0.03), 0.50 (0.81) 65 5,000
0.05 65 (0.03), 620 (0.46) 5,000
Hardy-Weinberg Equilibrium and Mendelian Randomization 509
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0.4 (j1   kj¼0.09, p ¼ 0.05, N ¼ 5,000), and the median
difference is 38.6. The results for variations of homozygotes
(Web Table 9 (http://aje.oxfordjournals.org/)) were compa-
rable: a maximum of 3,686, a minimum of 0.19, and a me-
dian of 23.87.
The observed Q-Q plots in WTCCC controls are not dis-
similar to those observed for the 7 WTCCC case collections
(Web Figure 2 (http://aje.oxfordjournals.org/)). Figure 2
shows results for WTCCC controls and cases with bipolar
disorder. In all instances, there are considerably more high
v
2 values than expected, a situation that is more extreme in
the 7 WTCCC case collections. A similar result is observed
for the 30 studies of APOE (Figure 2). For Framingham
Study prostate cancer cases, the Q-Q plot is different, with
an inﬂection around v
2 values of 11.5 (Figure 2).
Table 6 shows a nonsigniﬁcant MR association observed
in the original study. This association becomes signiﬁcant
after the addition of missing persons (to give perfect HWE)
with intermediate phenotypes following 3 different criteria.
Note that deviations from HWE are not signiﬁcant in the
original study.
In Figure 3 we show, with an explanatory legend, the Web
tool written both to perform a Pearson v
2 HWE test and,
Table 5. Hardy-Weinberg v
2 Values (in Parentheses) for Particular Combinations of Allele
Frequency, Gain/Loss of Heterozygotes, and Sample Size
Allele Frequency Gain/Loss, % Sample Size
0.05 65 5,000 (0.12), 100,000 (2.36)
0.05 (0.12), 0.50 (3.14) 65 5,000
0.05 65 (0.12), 620 (2.23) 5,000
Figure2. Q-Q plotscomparingthe expected and observedv
2valuesfor controlsfrom theWellcomeTrustCase ControlConsortium (WTCCC)(6)
and one of the 7 case collections (cases of bipolar disorder). The Q-Q plots (which are similar) for all of the other 6 case collections can be seen in
Web Figure 2 (http://aje.oxfordjournals.org/). Also shown is a Q-Q plot comparing the expected and observed v
2 values for 30 studies of the
apolipoprotein E (APOE) polymorphism taken from the literature and a Q-Q plot comparing the expected and observed v
2 values for Framingham
Study (7) prostate cancer cases. A) Q-Q plot for WTCCC controls; B) Q-Q plot for WTCCC bipolar disorder cases; C) Q-Q plot for the 30 APOE
studies; D) Q-Q plot for the Framingham prostate cancer cases.
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type would be under perfect HWE (v
2 ¼ 0).
DISCUSSION
Missingness of subjects of a particular genotype group
from a population sample may be due to chance, genotyping
assay errors, or clinical ascertainment bias related to that
genotype. We have examined chance variation of the ob-
served count for a particular genotype group (common or
rare homozygotes (1 > p > 0) and heterozygotes (1 >
p > 0.5)) in relation to HWE testing and missingness of
subjects from a population sample. We have illustrated the
differences between perfect HWE and ‘‘no statistically sig-
niﬁcant deviation from HWE’’ in terms of possible subject
missingness. While such missingness could be attributed to
chance, it could equally well represent a clinical ascertain-
ment bias related to the genotype in question.
We demonstrate, in both genome-wide and speciﬁc pub-
lished data,despite high-quality data from the use of modern
methods, a clear excess of inﬂated (though not necessarily
statistically signiﬁcant) v
2 values, pointing either to residual
erroneous typing or to sample ascertainment biases. We also
present an approach and a Web tool for estimating possible
missingness by genotype within HWE analyses and a ﬂow
Table6. Effecton MendelianRandomization of BothDeviationsFromHardy-Weinberg Equilibrium andAdditions of MissingPersonsto Conform
to Perfect Hardy-Weinberg Equilibrium
a
Original
Study
Addition of Missing
Persons
b
Addition of Missing
Persons
c
Addition of Missing
Persons
d
MR Probability HWE x
2 MR Probability HWE x
2 MR Probability HWE x
2 MR Probability HWE x
2
0.0697 3.32 0.0477 0 2.91
 16 0 7.54
 30 0
Abbreviations: HWE, Hardy-Weinberg equilibrium; MR, Mendelian randomization.
a Analyses were carried out in a study of 10,000 persons with information on a genetic marker, an intermediate trait, and a disease outcome.
b Additionof 507 homozygote1 subjectswith a diseasedstatus and a meanbodymass index (weight (kg)/height(m)
2) equalto that of subjectsin
the original study.
c Addition of 507 homozygote 1 subjects with a diseased status and a body mass index greater than or equal to the highest 75th percentile of
body mass index for subjects in the original study.
d Addition of 507 homozygote 1 subjects with a diseased status and a body mass index greater than or equal to the highest 95th percentile of
body mass index for subjects in the original study.
Figure 3. Illustration of output from the Web tool (see Materials and Methods section and http://www.oege.org/software/hwe-mr-calc.shtml)
developed for Hardy-Weinberg equilibrium (HWE) analysis with estimations of possible ascertainment bias. In this example, the user input was
genotype group counts of 5,236 (commoner homozygotes), 4,050 (heterozygotes), and 714 (rarer homozygotes). The output v
2 value of 3.32
approaches but does not reach statistical signiﬁcance (at P < 0.05). The table of solutions for perfect HWE (v
2 ¼ 0) shows, in red, the count that
would be necessary if one of the 3 groups were accordingly adjusted. The differences from observed counts identify the possible missingnesses or
excesses, which can then be considered in a subsequent genotype-phenotype or Mendelian randomization analysis. Hz, homozygotes; SNPs,
single nucleotide polymorphisms. (TRG, SR, and INMD represent the authors’ initials.)
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the bounds of effect of possiblegenotype-dependent missing-
ness in MR analyses.
The results from the analyses of the Q-Q plots in WTCCC
controls and cases, in Framingham prostate cancer cases,
and in APOE studies published in the literature suggest
that there might be missingness in all of these studies, since
the observed distribution of v
2 values does not ﬁt well the
expected distribution for 1 degree of freedom. Other possi-
ble reasons for the deviations from HWE (particularly in
controls but also in cases) may include residual technical
issues with SNP assays and SNP calling, ascertainment bias,
sample subdivision (stratiﬁcation or admixture), and other
unknown or unrecognized sequence variation confounding
SNP assays. Overall, these points put into perspective the
difference between the often-used results statement ‘‘in
HWE’’ and the reality ‘‘not statistically signiﬁcantly deviant
from HWE.’’ They also draw attention to the general excess
of statistically signiﬁcant deviations from HWE still evident
in both focused and genome-wide studies, and to the general
considerations necessary to be able to deploy HWE testing
to be maximally informative regarding sample collection.
These points are relevant to MR studies. In a very large
(outbred) population, there should be exact HWE at the
point of conception. That is the moment at which the in-
tention to randomize takes place, making MR directly com-
parable with a model randomized controlled trial. However,
taking a population sample in later life and entering the
successfully genotyped set into an MR analysis has the po-
tential to violate the principle of ‘‘intention to analyze.’’
It is outside the scope of this discussion to consider in
detail the issue of biases in genotyping, except to note that
even minor biases ranging from technical issues to covert
null alleles (8), if unrecognized, may defeat the value of
HWE assessment of the sample. A large sample size, which
is necessary anyway in genetic epidemiologic studies of
markers of small effect, is also important in increasing the
power of the HWE test of the sample. In addition to being
a test of genotype-dependent clinical ascertainment bias, the
HWE test, in population genetics terms, assumes the ab-
sence of migration, mutation, natural selection, and assorta-
tivemating. Under these conditions, genotype frequencies at
any locus are a function of the allele frequencies (p
2,2 pq,
and q
2), forming the basis of the standard HWE test (2, 3).
Where genome-wide data are available, ancestral outliers
may be inferred (and excluded) based on their constellation
of SNP alleles (6). Where single markers are studied, re-
liance remains on good clinical data about ancestry.
We have created (Figure 3) a new Web program (http://
www.oege.org/software/hwe-mr-calc.shtml) which under-
takes a standard Pearson v
2 test following Hardy (2) and
Weinberg (3)—that is, a parsimonious test based on ob-
served allele counts. In addition, noting that (2Npq)
2 ¼
4(Np
2)(Nq
2), it is possible to use the ratio of 2 genotype
counts, assumed unbiased, to estimate what should be the
third genotype count under perfect HWE (v
2 ¼ 0). The pro-
gram calculates this for the 3possible combinations. For any
genotype group (suspected in advance or not), missingness
(or excess) relativeto the observedcount can thus be consid-
ered. The genetic model (recessive/threshold, codominant/
additive, heterotic, X-linked, etc.) must ﬁrst be speciﬁed
in order to conduct genotype-phenotype or MR analyses
and to consider genotype-dependent missingness (scheme
in Figure 4).
1. For the threshold model, it may be possible to specify
which homozygote group should be checked for missing-
ness. If A were observed whereas the other 2 genotype
groups gave the prediction that B was expected, then
B minus A dummy subjects can be introduced into an
MR analysis, assigned a distribution of the intermediate
trait values that is characteristic of their genotype group,
and all assigned either disease-positive or disease-
negative. This allows reasonable bounds of inference to
be characterized in relation to possible genotype-related
missingness. If it is unknown in advance which homozy-
gous group might be in deﬁcit, then both models should
be examined.
2. For heterosis, the heterozygous excess or deﬁciency can
be considered along the same lines as in point 1 above.
3. For the additive model, HWE testing may not be sensi-
tive to ascertainment biases. For the codominant (addi-
tive) model, consider that each allele q is subject to an
ascertainment bias k (0 < k < 1, but typically k will be
quite near 1 for complex traits). Thus, the ascertained
heterozygote frequency will be 2kpq and the homozygote
frequency will be k
2q
2. However, since k
2q
2 is (kq)
2, this
will retain perfect HWE with new apparent q# ¼ kq and
p# ¼ 1   q#. Where k is near 1, the loss of subjects could
be stated as loss m, where k ¼ 1   m and k
2 is approx-
imately 1   2m (the m
2 term being negligible); so then,
even under an additive model of loss (twice as much—
that is, 2m loss of a homozygote group vs. the m loss of
heterozygotes), relative genotype counts will remain
very near HWE. This means that, under the additive
model, the sample may show little or no deviation from
HWE. However, life-course information on allele fre-
quencies will be useful to conﬁrm that effect sizes in
genotype-trait-disease have not been underestimated,
and this emphasizes the value of having data on allele
frequencies in a large-scale early-life cohort that is
matched to the general population.
It is impossible to prove that possible missing subjects
were not unusually extreme for either an intermediate trait
or disease status (e.g., numerous genotypes predispose to
more than 1 disease), although sometimes reductio ad
absurdum may sufﬁce—for example, in a study of 100,000
persons and a possible ascertainment-driven missingness of
10 homozygotes, the missingness might be incapable of
having any bearing on genotype-intermediate trait-clinical
outcome associations even if those 10 subjects had an
‘‘absurd’’value for an intermediate trait or clinical outcome.
Even if this is not possible, it may be considered unlikely
(though not proven) that a genotype could have driven
missingness. For a gene believed only to be expressing
ahighlyspeciﬁcfunctioninlaterlife,thismaybereasonable,
butforgeneswithpleiotropyandparticularlywithexpression
in early fetal development, there might be more concern.
Multifunctionality of the many forms recognized from
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asintheENCODE(EncyclopediaofDNAElements)Project
(9), microRNAs (10) with other regulatory functions, etc.,
arisingfrommanygenes,andothergenesinthesamelinkage
disequilibrium block (11) should be considered in drawing
a reasonable conclusion.
Theeffectsofmissingness(chancevs.genotype-dependent
clinical ascertainment) are no different in an MR study than
in any other genotype-phenotype (genetic association) study.
However, the consequences of misinference would be
different. In principle, a false-negative result may be ob-
tained by chance in any genotype-phenotype study, although
one hopes that genotype-dependent clinical ascertainment
bias might be evident with high-quality genotyping data
combined with attention to HWE testing. Indeed, this is
why case-control studies use HWE of controls (not cases)
Figure 4. Steps needed to utilize Hardy-Weinberg equilibrium (HWE) testing for possible biologic ascertainment in genotype-phenotype or
Mendelian randomization (MR) studies. HWD, Hardy-Weinberg disequilibrium.
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studies are undertaken because there is already a focus based
on knowledge of a potentially important association (albeit of
unknowndirection)betweenanintermediatetrait(e.g.,dietary
factor,bloodmeasure)andanoutcome(e.g.,diseaseevent).In
this case, if the genotype-outcome association draws a false-
negative inference (e.g., because persons with the genotype-
dependent outcome had failed to enter the study), the ﬁnding
ofimportant causality will have been falsely excluded. In this
paper,wehaveillustratedtheeffectsof‘‘Hardy-Weinbergun-
certainty’’ for ‘‘intention to MR’’; have identiﬁed general
strategies for gaining maximal information from the HWE
test; and have developed a Web tool and scheme which will
allowpossiblegenotype-dependentmissingnesstobefactored
into MR analyses.
The main limitation of our study is that the phenotypes of
any subjects missing or potentially missing in a real MR
study are unknown. Potentially missing subjects may have
had atypical intermediate trait values or disease status (or
other diseases related to the same genotype). While the
analytical scheme presented here takes account of missing-
ness based on ‘‘reasonable’’ trait values, one cannot predict
extremes; this would require tracking of a complete cohort
from conception throughout the life course.
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